At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
Dose-Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Feb 27, 2020·Updated Apr 24, 2026
In Brief
A Phase 2 clinical trial evaluating Dose-Placebo, Low Dose-VIS649, and 2 other interventions for Immunoglobulin A Nephropathy and 2 related conditions. Completed, enrolled 155 participants across 93 sites in 15 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunoglobulin A Nephropathy, Glomerular Disease, IgAN
CountriesAustralia, Canada, Hong Kong, India, Japan, Malaysia, Philippines, Singapore, South Korea, Spain, Sri Lanka, Taiwan, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartJul 2020
Primary CompletionMay 2023
Study CompletionJun 2023
TodayJul 2026
First PostedFeb 27, 2020
Enrollment StartJul 20, 2020
Primary CompletionMay 19, 2023
Study CompletionJun 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.3 years ago
Interventions
Dose-Placebodrug
Unit Dose Strength - 0.9%.
Low Dose-VIS649drug
Dose Level = Low
Medium Dose-VIS649drug
Dose Level = Medium
High Dose-VIS649drug
Dose Level = High